Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why New Coronavirus Strains Could Boost Pfizer and Moderna's Fortunes

By Keith Speights - Dec 29, 2020 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mutations could mean more money for the two drugmakers.

It was the last thing anyone wanted to hear in the waning days of 2020. Researchers identified a new strain of the SARS-CoV-2 coronavirus that causes COVID-19. And it could be a lot more contagious than the current coronavirus strain that has wreaked havoc across the world.

European countries have implemented travel restrictions to try to prevent the spread of the new coronavirus strain, which scientists refer to as B.1.1.7. However, it's likely that such efforts are too late. 

The obvious question on many people's minds is: Will the vaccines from Pfizer ( PFE 2.54% ) and Moderna ( MRNA -4.36% ) that are already being distributed in the U.S. still be effective against the new strain? So far, the answer to that question appears to be "yes." However, more research is being conducted.

While all of this is understandably concerning, there's a silver lining for some investors. Here's why the coronavirus strains could actually boost Pfizer and Moderna's fortunes.

Man with hands on hips looking at computer images of coronavirus and a world map with a city street in the background.

Image source: Getty Images.

More mutations could mean greater earnings

Americans are accustomed to receiving vaccines. But there are some big differences in the vaccines that we get.

For example, tetanus shots are usually given around four weeks apart. A third shot usually is administered within six to 12 months later. After that, booster shots are needed every 10 years. Getting a flu vaccine, on the other hand, is an annual event.

One key reason why flu vaccines are required so much more frequently is that the influenza virus mutates at a rapid rate. Vaccines must be tweaked to provide protection against the new flu strains.

Research has found that SARS-CoV-2 has a lower mutation rate than the seasonal flu. However, the coronavirus definitely is mutating, as the more contagious strain identified in the U.K. underscores. For Pfizer, along with its partner BioNTech ( BNTX -2.97% ), and Moderna, these mutations could generate more money over the long run.

Bernstein analyst Ronny Gal projects a $40 billion COVID-19 vaccine market in 2021 that will taper off significantly after next year. However, future mutations to the coronavirus could cause the current versions of vaccines to be less effective. If that happens, the market size for Pfizer and Moderna will be much bigger in 2022 and beyond than Gal is predicting. 

The mRNA advantage

Other coronavirus vaccines could be on the way soon. AstraZeneca hopes to win U.K. authorization for its AZD1222 this week. The British drugmaker should report its results from a pivotal U.S. study in late January. Johnson & Johnson expects to seek U.S. emergency use authorization for its COVID-19 vaccine in February.

However, Pfizer and Moderna could have a key competitive advantage due to their similar approaches. Both companies harness messenger RNA (mRNA) to spur the body's cells to produce a replica of the spike protein that's on the surface of SARS-CoV-2. 

Pfizer and Moderna were able to get to market more quickly than their rivals in part because of the rapid development of a vaccine that mRNA technology makes possible. Once the genetic sequence of a virus is known, mRNA-generated antigens can be quickly produced and tested in preclinical studies with the best candidate advancing into clinical testing.

This rapid development and testing capability would likely become even more important in an environment where the coronavirus mutated frequently. 

Too soon 

Does the emergence of the U.K. coronavirus strain mean that Pfizer and Moderna are poised to dominate the COVID-19 vaccine market? No. For that matter, it's too soon to know if other future SARS-CoV-2 mutations will make a material financial difference for the companies.

However, it's definitely possible that new coronavirus strains could work to the benefit of Pfizer and Moderna down the road. Moderna seems likely to be the bigger winner since it owns the full rights to its COVID vaccine, while Pfizer and BioNTech split the revenue for their vaccine.

Moderna is up close to 500% in 2020. The biotech stock could move much higher if mutations with the coronavirus make the COVID-19 vaccine market more like the seasonal flu vaccine market than the tetanus vaccine market.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$352.43 (-4.36%) $-16.08
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.73 (2.54%) $1.33
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.83 (-1.26%) $0.70
Johnson & Johnson Stock Quote
Johnson & Johnson
$155.93 (-2.39%) $-3.82
BioNTech SE Stock Quote
BioNTech SE
$351.74 (-2.97%) $-10.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.